Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine

  title={Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine},
  author={S. Doggrell and J. Hancox},
  journal={Expert Opinion on Drug Safety},
  pages={131 - 138}
  • S. Doggrell, J. Hancox
  • Published 2014
  • Medicine
  • Expert Opinion on Drug Safety
  • Introduction: Domperidone is a dopamine D2-receptor antagonist developed as an antiemetic and prokinetic agent. Oral domperidone is not approved in the United States, but it is used in many countries to treat nausea and vomiting, gastroparesis and as a galactogogue (to promote lactation). The US Food and Drug Administration (FDA) have issued a warning about the cardiac safety of domperidone. Areas covered: The authors undertook a review of the cardiac safety of oral domperidone. Expert opinion… CONTINUE READING
    52 Citations
    Severe Proarrhythmic Potential of the Antiemetic Agents Ondansetron and Domperidone
    • 9
    Use of Domperidone to Increase Breast Milk Supply
    • L. Grzeskowiak
    • Medicine
    • Journal of human lactation : official journal of International Lactation Consultant Association
    • 2014
    • 1
    • PDF
    Ghrelin Agonists as Emerging Prokinetic Agents.
    • J. Tack, M. Corsetti
    • Medicine
    • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
    • 2015
    • 2
    5-Hydroxytryptamine3 receptor antagonists and cardiac side effects
    • 25
    Effect of Chronic Domperidone Use on QT Interval
    • 7
    Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis
    • 41
    • Highly Influenced


    Domperidone: A Peripherally Acting Dopamine2-Receptor Antagonist
    • J. Barone
    • Medicine
    • The Annals of pharmacotherapy
    • 1999
    • 209
    Domperidone: Review of Pharmacology and Clinical Applications in Gastroenterology
    • 202
    • Highly Influential
    Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders
    • 109
    • Highly Influential
    • PDF
    Low safety index of domperidone: mechanism for increased odds ratio for sudden cardiac death
    • 12
    • PDF
    A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting.
    • 8
    Comparison of the Effects of Metoclopramide and Domperidone on HERG Channels
    • 38
    Domperidone: Limited Benefits With Significant Risk for Sudden Cardiac Death
    • L. Hondeghem
    • Medicine
    • Journal of cardiovascular pharmacology
    • 2013
    • 35
    • Highly Influential
    Pharmacokinetics and Dose Proportionality of Domperidone in Healthy Volunteers
    • 39
    Domperidone and sudden cardiac death: How much longer should we wait?
    • 14